

VERSION WITH MARKINGS TO SHOW CHANGES MADE

SEQUENCE LISTING

Please incorporate the Sequence Listing as attached herein.

IN THE SPECIFICATION

On page 19, lines 8-23, please replace the current paragraph with the following:

Ten ng of cDNA/reaction was analyzed for expression of selected chemokines, chemokine receptors, and ubiquitin on a GeneAmp 5700 Sequence Detector (PE Applied Biosystems) in a 25 µL reaction. Expression of chemokines and chemokine receptors was detected using primers and probe (PE Applied Biosystems) with TaqMan Universal Master Mix (PE Applied Biosystems) or primers alone and SYBR Green PCR Master Mix (PE Applied Biosystems). TaqMan reagents to detect expression of given chemokines or their receptors were extensively tested to verify that they only recognized the appropriate target sequence and not closely related family members. Ubiquitin was detected using 200 nM primers (F: CACTTGGTCCTGCGCTTGA (SEQ ID NO: 1); R: CAATTGGGAATGCAACAACCTTAT (SEQ ID NO: 2)) with SYBR Green PCR Mater Mix. The data was analyzed to calculate a cycle threshold value (Ct) for each sample with GeneAmp 5700 SDS Software (PE Applied Biosystems). The relative level of CCL18 mRNA in the tissue using the following formula: $1.8(Ct \text{ of ubiquitin} - Ct \text{ of gene of interest})10,000$ for each sample. Mean and standard error were calculated for each group.

On page 19, line 26 to page 20, line 12, please replace the current paragraph with the following:

Statistical analysis was performed with JMP 3.2.2 (SAS Institute, Inc.). The TaqMan data for the relative level of chemokine and chemokine ~~reepeters~~ receptors was log transformed and a one-way ANOVA performed. The log transformed of chemokine and chemokine ~~reepeter~~ receptor level was used as the dependent variable and the disease group was used as the independent variable. All groups were compared to the control group using a modified Student *t*-test, Dunnett's method.

On page 21, lines 11-13, please replace the current paragraph with the following:

All citations herein are ~~incorporated~~ incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

IN THE CLAIMS

Please cancel claims 4, 5, and 7.

Please add claims 8-13 as follows:

8. A method for treating an inflammatory bowel disease in a mammal, said method comprising administering to said mammal an effective amount of an agent to decrease signaling mediated by MIP-3 α .
9. The method of Claim 8, wherein said inflammatory bowel disease is an ulcerative colitis.
10. The method of Claim 8, wherein said inflammatory bowel disease is Crohn's disease.
11. The method of Claim 8, wherein said agent decreases symptoms of the inflammatory bowel disease.
12. The method of Claim 8, wherein said agent is an antibody that binds to MIP-3 α .
13. The method of Claim 8, wherein said agent is an antibody that binds to CCR6.